Thoma Bravo partner Hudson Smith discusses the private equity firm’s recent acquisition of clinical trial workflow software provider Greenphire in an interview with Mergers & Acquisitions. A rebound from Covid-related trial delays and secular tailwinds for healthcare IT can buoy the firm’s new investment and the broader market.
To read the entire story, you must be logged in.
Please log in now or register with us.
